Anavex Life Sciences Corp. (AVXL) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
630 5TH AVENUE NEW YORK, NY 10111 |
| State of Incorp. | |
| Fiscal Year End | September 30 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2025 MRQ | 12/31/2024 MRQ | 9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 120,775 | 132,187 | 151,024 | 149,158 | 152,108 | 29,249 | |||
| Cash and cash equivalent | 120,775 | 132,187 | 151,024 | 149,158 | 152,108 | 29,249 | |||
| Receivables | 2,557 | 2,449 | 2,709 | 3,193 | 9,137 | 4,849 | |||
| Prepaid expense | 356 | 444 | |||||||
| Total current assets: | 123,332 | 134,636 | 153,733 | 152,350 | 161,600 | 34,542 | |||
| Noncurrent Assets | |||||||||
| Regulated entity, other noncurrent assets | 16 | ||||||||
| Total noncurrent assets: | 16 | ||||||||
| Other undisclosed assets | 711 | 931 | 653 | 354 | |||||
| TOTAL ASSETS: | 124,043 | 135,567 | 154,386 | 152,705 | 161,616 | 34,542 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 12,299 | 14,462 | 11,617 | 11,067 | 10,355 | 7,306 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | ✕ | 1,297 | ||||
| Accounts payable | 4,567 | 9,627 | 4,322 | 3,825 | 4,740 | 3,989 | |||
| Accrued liabilities | 7,732 | 4,835 | 7,295 | 5,945 | 5,615 | 3,317 | |||
| Deferred revenue | 829 | ||||||||
| Total current liabilities: | 13,128 | 14,462 | 11,617 | 11,067 | 10,355 | 7,306 | |||
| Noncurrent Liabilities | |||||||||
| Other undisclosed liabilities | 842 | 917 | (854) | 444 | |||||
| Total liabilities: | 13,128 | 15,304 | 12,534 | 10,214 | 10,798 | 7,306 | |||
| Equity | |||||||||
| Equity, attributable to parent | 110,915 | 120,263 | 141,852 | 142,491 | 150,818 | 27,237 | |||
| Common stock | 85 | 85 | 82 | 78 | 76 | 62 | |||
| Additional paid in capital | 459,012 | 456,249 | 434,839 | 387,977 | 348,328 | 186,852 | |||
| Accumulated deficit | (348,182) | (336,071) | (293,069) | (245,564) | (197,586) | (159,677) | |||
| Total equity: | 110,915 | 120,263 | 141,852 | 142,491 | 150,818 | 27,237 | |||
| TOTAL LIABILITIES AND EQUITY: | 124,043 | 135,567 | 154,386 | 152,705 | 161,616 | 34,542 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2025 TTM | 12/31/2024 TTM | 9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues (Other Income) | 444 | |||||||
| Gross profit: | 444 | |||||||
| Operating expenses | (55,176) | (52,877) | (55,756) | 50,986 | (42,001) | (31,088) | ||
| Other undisclosed operating loss | (101,972) | |||||||
| Operating loss: | (55,176) | (52,877) | (55,756) | (50,986) | (41,557) | (31,088) | ||
| Nonoperating income | 8,599 | 9,875 | 8,258 | 3,366 | 4,360 | 4,830 | ||
| Gain (loss), foreign currency transaction, before tax | (303) | 189 | (40) | (904) | (267) | 126 | ||
| Interest and debt expense | 59 | |||||||
| Other undisclosed loss from continuing operations before equity method investments, income taxes | (59) | (444) | ||||||
| Loss from continuing operations before equity method investments, income taxes: | (46,577) | (43,002) | (47,498) | (47,619) | (37,641) | (26,258) | ||
| Other undisclosed income from continuing operations before income taxes | ||||||||
| Loss from continuing operations before income taxes: | (46,577) | (43,002) | (47,498) | (47,619) | (37,641) | (26,258) | ||
| Income tax expense | (38) | (7) | (717) | (535) | (23) | |||
| Other undisclosed income from continuing operations | 124 | |||||||
| Loss from continuing operations: | (46,491) | (43,002) | (47,505) | (48,336) | (38,176) | (26,280) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (48,336) | (38,176) | (26,280) | |
| Net loss: | (46,491) | (43,002) | (47,505) | (48,336) | (38,176) | (26,280) | ||
| Other undisclosed net income attributable to parent | 358 | 268 | ||||||
| Net loss available to common stockholders, diluted: | (46,491) | (43,002) | (47,505) | (47,978) | (37,909) | (26,280) | ||
Comprehensive Income ($ in thousands)
| 6/30/2025 TTM | 12/31/2024 TTM | 9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (46,491) | (43,002) | (47,505) | (48,336) | (38,176) | (26,280) | ||
| Comprehensive loss, net of tax, attributable to parent: | (46,491) | (43,002) | (47,505) | (48,336) | (38,176) | (26,280) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.